Please refer to the period-after-opening symbol (open jar symbol) on the label of the product
This powerful combination of methionine, inositol, choline, and B12 helps your body burn fat more efficiently while increasing energy levels
The most clearly defined groups who may be considered in future include individuals with: Metabolic dysfunction-associated steatotic liver disease (MASLD) particularly those with concurrent obesity, type 2 diabetes, or metabolic syndrome Metabolic dysfunction-associated steatohepatitis (MASH) the progressive inflammatory subtype associated with fibrosis and risk of cirrhosis Obesity with elevated liver enzymes (ALT/AST) where hepatic steatosis has been confirmed on imaging Type 2 diabetes with evidence of hepatic fat accumulation , where current glucose-lowering therapies have not adequately addressed liver disease Patients with significant hepatic fibrosis (stage F2 or above) represent a group with particularly high unmet need, as there are currently no licensed pharmacological treatments specifically approved for MASH in the UK
NeuroReport 8:31233126 Saxena AR, Gorman DN, Esquejo RM, Bergman A, Chidsey K, Buckeridge C, Griffith DA, Kim AM (2021) Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
The unopened original vial is the recommended container until the moment of reconstitution
Mitchell JL, Lyons HS, Walker JK, et al
